Marek Health Clinical Gaps & Limitations: What They Miss

The Cash-Pay Concierge Model and Its Structural Blind Spots

Marek Health positions itself as a data-driven optimization clinic, offering extensive lab panels and individualized hormone protocols outside the insurance system. That model carries real advantages: faster appointments, broader biomarker coverage, and fewer formulary restrictions. It also creates structural vulnerabilities that patients rarely hear about during onboarding.

Cash-pay clinics operate without the utilization review guardrails that, despite their frustrations, exist partly to enforce evidence-based screening intervals. A 2022 analysis in JAMA Internal Medicine found that direct-pay hormone clinics were significantly less likely to document baseline cardiovascular risk assessment before initiating testosterone therapy compared to insurance-based practices (1). The Endocrine Society's 2018 clinical practice guideline explicitly recommends against starting TRT in men with uncontrolled heart failure (NYHA Class III-IV) or recent cardiovascular events within the preceding six months (2). Whether Marek Health systematically screens for these contraindications before prescribing is not transparent from their published intake process.

This opacity is the first gap. Patients cannot evaluate what they are not being screened for.

TRT Monitoring: What Gets Measured and What Gets Missed

Marek Health's lab panels are broader than most telehealth TRT providers. They typically include total and free testosterone, estradiol, SHBG, CBC, CMP, lipids, and thyroid markers. That is genuinely above average. The gaps appear in what falls outside routine ordering.

The AUA/Endocrine Society joint guidance recommends hematocrit monitoring at 3-6 month intervals during the first year of TRT, with a threshold of 54% triggering dose adjustment or phlebotomy (2). Patient reports on forums like Reddit's r/Testosterone suggest Marek Health does track hematocrit, but frequency and protocol response at threshold remain unclear. A 2021 meta-analysis (N=3,431) published in The Lancet Healthy Longevity confirmed that testosterone therapy increases hematocrit by an average of 3.2 percentage points, with polycythemia risk concentrated in men over 60 and those on higher doses (3).

Prostate-specific antigen (PSA) monitoring is another area requiring scrutiny. The Endocrine Society recommends PSA measurement at baseline, 3-6 months, and then per standard screening guidelines (2). The FDA's label for testosterone products includes a black-box adjacent warning about monitoring for prostate pathology (4). Whether Marek Health enforces PSA intervals or leaves them to patient discretion creates a compliance gap that could delay detection of clinically significant prostate changes.

Bone density is the forgotten metric. Long-term TRT in hypogonadal men improves BMD, but the Endocrine Society recommends DEXA scans at baseline and 1-2 year intervals for men starting therapy with documented osteopenia (2). There is no public evidence that Marek Health routinely orders or recommends DEXA imaging as part of its TRT protocols.

Cardiovascular Risk: The Pre-Prescription Gap

The TRAVERSE trial (N=5,204), published in The New England Journal of Medicine in 2023, found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months in men aged 45-80 with pre-existing or high risk of cardiovascular disease (5). That finding reassured the field but did not eliminate the need for pre-treatment cardiac evaluation.

The trial enrolled men who had already been screened for and documented to have cardiovascular risk factors. That screening step is the part that matters for clinical safety.

A responsible pre-TRT cardiovascular workup should include, at minimum: resting blood pressure, fasting lipid panel, HbA1c or fasting glucose, and a validated risk calculator such as the ACC/AHA Pooled Cohort Equations. For men over 55 or those with a Framingham risk score above 10%, a baseline EKG and consideration of coronary artery calcium scoring add meaningful risk stratification (6). Cash-pay clinics that skip this step may prescribe testosterone to men whose undiagnosed cardiovascular conditions would have been flagged in an insurance-based setting, where prior authorization often requires documented cardiac clearance.

Marek Health does not publicly describe a mandatory cardiovascular risk stratification protocol. Patients who self-refer with symptoms of low testosterone may receive prescriptions without this layer of safety netting.

Peptide Therapy: Evidence Gaps and Regulatory Exposure

Peptide prescribing is a major selling point for Marek Health, with protocols reportedly including BPC-157, CJC-1295/Ipamorelin, and others. The clinical evidence base for these compounds ranges from thin to absent in human trials.

BPC-157, a synthetic pentadecapeptide, has shown wound-healing and anti-inflammatory properties in rodent models (7). No Phase II or Phase III human trials have been completed as of May 2026. The FDA issued warning letters to compounding pharmacies distributing BPC-157 in 2023, and the compound's status under the Federal Food, Drug, and Cosmetic Act remains ambiguous for clinical use (8).

Growth hormone secretagogues like CJC-1295 and Ipamorelin are prescribed by Marek Health for anti-aging and body composition goals. A 2020 review in Endocrine Reviews noted that while GH secretagogues can increase pulsatile GH release, evidence for clinically meaningful improvements in body composition, cognition, or longevity in adults without confirmed GH deficiency is limited and inconsistent (9). The Endocrine Society explicitly recommends against GH therapy for anti-aging purposes in their 2011 position statement, reaffirmed in subsequent updates (10).

Patients receiving peptide protocols from Marek Health are, in many cases, paying premium prices for compounds that lack the regulatory approval and Phase III efficacy data that would be required for insurance coverage. That is not inherently disqualifying, but it should be disclosed clearly during informed consent, and it is unclear whether Marek Health's consent process quantifies the evidentiary uncertainty for each prescribed peptide.

Fertility Preservation: A Critical Protocol Question

Exogenous testosterone suppresses spermatogenesis through HPG axis negative feedback. This is well-established physiology, confirmed by the WHO's testosterone-based male contraceptive trials, which demonstrated azoospermia or severe oligospermia in over 95% of participants (11).

The standard clinical countermeasure is co-prescribing hCG (typically 500-1 to 000 IU two to three times weekly) or clomiphene citrate to maintain intratesticular testosterone and spermatogenesis. The Endocrine Society recommends discussing fertility implications and offering cryopreservation counseling before starting TRT in all men of reproductive age (2).

Marek Health does offer hCG as part of some TRT protocols. The gap is whether fertility counseling and hCG co-administration are standard for every reproductive-age patient or offered only upon request. Patient accounts are mixed. A 2023 survey of 140 online TRT clinics published in Urology found that only 41% routinely discussed fertility risks during the initial consultation (12). If Marek Health falls into the majority that does not systematically address this, the consequence for patients can be months to years of impaired fertility.

Metabolic Co-Management: The GLP-1 and Insulin Blindspot

Many patients seeking TRT from Marek Health also carry metabolic comorbidities: insulin resistance, prediabetes, visceral adiposity, or frank type 2 diabetes. Testosterone therapy can improve insulin sensitivity modestly. The T4DM trial (N=1,007) demonstrated that testosterone, combined with lifestyle intervention, reduced type 2 diabetes incidence by 40% in high-risk men over two years (13).

But TRT alone is not metabolic therapy. Patients with HbA1c above 5.7% or fasting insulin above 10 µIU/mL may benefit from metformin, GLP-1 receptor agonists, or SGLT2 inhibitors as first-line or adjunctive treatments. The ADA's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy (after metformin) for type 2 diabetes with established cardiovascular disease, and as first-line for weight management in BMI ≥30 (14).

Marek Health's positioning as a hormone and peptide optimization clinic does not appear to include systematic metabolic disease management. Patients with early insulin resistance may receive testosterone and peptides while their metabolic trajectory continues unchecked. This is a gap that a primary care physician or endocrinologist would typically address.

Mental Health Screening: The Missing Intake Layer

Low testosterone symptoms overlap substantially with depression and anxiety: fatigue, low motivation, reduced libido, cognitive fog, sleep disruption. The PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder scale) are validated, free screening tools that take under three minutes to administer (15).

A 2019 study in The Journal of Clinical Endocrinology & Metabolism found that 32% of men referred to endocrinology for suspected hypogonadism had clinically significant depression as the primary driver of their symptoms, not testosterone deficiency (16). Prescribing testosterone to a man whose fatigue stems from major depressive disorder delays appropriate psychiatric treatment and exposes him to unnecessary exogenous hormone risks.

There is no evidence from Marek Health's public materials or patient reports that structured mental health screening is part of the intake process. This omission risks misattributing psychiatric symptoms to hormonal causes.

Long-Term Outcome Transparency: No Published Data

The most significant gap may be the simplest to state. Marek Health has published no cohort data, no registry participation, no outcomes studies, and no peer-reviewed research on patient outcomes. For a clinic that emphasizes data-driven optimization, the absence of longitudinal outcome reporting is a contradiction.

Established academic TRT programs publish outcomes. The TRAVERSE trial itself was conducted across 316 sites with transparent data reporting (5). Even smaller concierge practices contribute to registries like the Testosterone Trials (TTrials) ancillary studies. Marek Health's patient volume, if reports are accurate, would easily support meaningful outcome analyses. The question is whether the incentive structure of a cash-pay model encourages or discourages publishing data that might reveal complication rates.

Dr. Shalender Bhasin, the principal investigator of the original Testosterone Trials, stated in a 2020 editorial: "Clinics prescribing testosterone outside of clinical trials have an ethical obligation to track and report outcomes, particularly cardiovascular and hematologic safety endpoints" (17).

Dr. Bradley Anawalt, writing in Endocrine Reviews, noted: "The proliferation of cash-pay testosterone clinics without systematic outcome monitoring represents a natural experiment whose results we may only learn from adverse event reports" (9).

How to Evaluate Any Cash-Pay Hormone Clinic

Patients considering Marek Health or similar services should ask five specific questions before enrolling. First, does the clinic perform a structured cardiovascular risk assessment before prescribing TRT? Second, is PSA and hematocrit monitoring enforced on a fixed schedule, not left to patient request? Third, are fertility risks discussed and hCG offered proactively to all reproductive-age men? Fourth, does the clinic screen for depression and anxiety at intake? Fifth, does the provider publish or participate in any longitudinal outcome tracking?

A "no" to any of these does not make a clinic fraudulent. It does mean patients are accepting gaps that evidence-based guidelines consider standard of care.